1Genentech,
Inc., South San Francisco, CA, United States; 2NeuroRX Research,
Montreal, Quebec, Canada; 3Genentech Inc, South San Francisco, CA,
United States

Several single site resting-state fMRI studies
(RS-fMRI) have shown that brain functional connectivity metrics are altered
in Alzheimer Disease (AD) patients. Exploratory RS-fMRI was included in two
global Phase II studies of a novel AD drug. We report here fMRI data quality
control procedures and observed quality metrics from screening and very early
on-treatment scans. Subject tolerance and protocol compliance was good. In
spite of heterogeneous scanning equipment and variable raw SNR across sites,
the data pre-processing pipeline resulted in consistent processed data
quality metrics, with few scans that could not be used for subsequent
functional connectivity analysis.